Numinus Wellness fights for survival after 90% stock collapse in 2026

Numinus Wellness faces a critical period as its stock price collapsed by 90% in late 2025 and early 2026. The company's shares fell from 0.0500 CAD on December 22, 2025, to just 0.0050 CAD by February 13, 2026, slashing its market value to around 13.87 million EUR. Investors and analysts are now watching closely to see if the firm can stabilise operations and restore confidence after months of uncertainty.

The sharp decline in Numinus's share price followed a prolonged trading halt at the end of 2025. Administrative challenges and delayed financial reporting added to investor concerns. Market observers stress that the company must now release audited financial results on time and confirm full regulatory compliance to secure future funding.

Meanwhile, competitors in the psychedelics and wellness sector are making strategic moves. Psyence Biomedical strengthened its supply chain by finalising a put-option deal with PsyLabs for pharmaceutical-grade psychedelics. Cybin Inc., however, disappointed investors with a larger-than-expected loss, reporting an EPS of -$0.72. In contrast, Canopy Growth saw gains after strong quarterly earnings and a series of acquisitions in the cannabis market.

Numinus aims to regain trust by resuming a regular reporting cycle. The company's future depends on proving its stability as a provider of clinical trial services. With the stock market today remaining volatile, capital flows are shifting toward firms with clear growth strategies or solid operational footing.

Numinus Wellness must now demonstrate operational stability to recover from its recent stock collapse. The timely release of financial data and proof of compliance will be key to attracting new investments. As competitors advance their own strategies, the company's ability to solidify its position in clinical services will determine its next steps.